By Colin Kellaher
Regeneron Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended conditional marketing approval of linvoseltamab for certain adults with the blood cancer multiple myeloma.
Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have shown disease progression on the last therapy.
The Tarrytown, N.Y., biotechnology company said the European Commission, which generally follows the CHMP's advice, is expected to announce a final decision in the coming months.
The U.S. Food and Drug Administration earlier this month accepted Regeneron's resubmitted application seeking approval of linvoseltamab and set a target action date of July 10 for a decision.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 28, 2025 07:34 ET (12:34 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。